StreetInsider.com News Articles

Form 4 AC Immune SA For: Jun 11 Filed by: Twyman Roy Ervin

Mon, 15 Jun 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260615/26644154.html

Form 4 AC Immune SA For: Jun 11 Filed by: Twyman Roy Ervin

Mon, 15 Jun 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260615/26644154.html

Form 4 AC Immune SA For: Jun 11 Filed by: AGUIAR-LUCANDER RENEE

Mon, 15 Jun 2026 06:59:00 -0400

si-local-file:///var/storage/secattach/20260615/26644007.html

Form 4 AC Immune SA For: Jun 11 Filed by: AGUIAR-LUCANDER RENEE

Mon, 15 Jun 2026 06:59:00 -0400

si-local-file:///var/storage/secattach/20260615/26644007.html

Form 4 AC Immune SA For: Jun 11 Filed by: Zuegel Martin

Mon, 15 Jun 2026 06:50:00 -0400

si-local-file:///var/storage/secattach/20260615/26643983.html

Form 4 AC Immune SA For: Jun 11 Filed by: Zuegel Martin

Mon, 15 Jun 2026 06:50:00 -0400

si-local-file:///var/storage/secattach/20260615/26643983.html

Form 4 AC Immune SA For: Jun 11 Filed by: Buetler Monika

Mon, 15 Jun 2026 06:40:00 -0400

si-local-file:///var/storage/secattach/20260615/26643939.html

Form 4 AC Immune SA For: Jun 11 Filed by: Buetler Monika

Mon, 15 Jun 2026 06:40:00 -0400

si-local-file:///var/storage/secattach/20260615/26643939.html

Form 4 AC Immune SA For: Jun 11 Filed by: June Carl Howard

Mon, 15 Jun 2026 06:32:00 -0400

si-local-file:///var/storage/secattach/20260615/26643904.html

Form 4 AC Immune SA For: Jun 11 Filed by: June Carl Howard

Mon, 15 Jun 2026 06:32:00 -0400

si-local-file:///var/storage/secattach/20260615/26643904.html

Form 6-K AC Immune SA For: Jun 11

Thu, 11 Jun 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260611/26636557.html

Form 6-K AC Immune SA For: Jun 11

Thu, 11 Jun 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260611/26636557.html

Form 6-K AC Immune SA For: Jun 11

Thu, 11 Jun 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260611/26632570.html

Form 6-K AC Immune SA For: Jun 11

Thu, 11 Jun 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260611/26632570.html

AC Immune receives $4 million grant for Parkinson's drug trial extension

Thu, 11 Jun 2026 07:00:52 -0400

AC Immune SA (NASDAQ: ACIU) announced it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to support extending Part 1 of its ongoing Phase 2 VacSYn trial of ACI-7104 in early Parkinson's disease.

The grant will fund a two-year extension of Part 1 of the trial, which is testing the company's anti-alpha-synuclein active immunotherapy. Final data from Part 1 of the VacSYn trial is expected in the second half of 2026.

The Vijay and Marie Goradia Charitable Foundation was established by Houston businessman and philanthropist Vijay Goradia and his wife Marie to support health, education,

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

Thu, 11 Jun 2026 07:00:00 -0400

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104
Planned extension of Part 1 will assess long-term safety and efficacy of ACI-7104 for an additional 2 years
Final data from Part 1 of VacSYn trial expected in H2 2026

Lausanne, Switzerland, June 11, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will receive a research grant of $4 million from The

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

Thu, 11 Jun 2026 07:00:00 -0400

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104
Planned extension of Part 1 will assess long-term safety and efficacy of ACI-7104 for an additional 2 years
Final data from Part 1 of VacSYn trial expected in H2 2026

AC Immune reports positive TDP-43 tracer data in ALS patients

Fri, 22 May 2026 07:00:37 -0400

AC Immune SA (NASDAQ: ACIU) announced preliminary Phase 1 data showing its TDP-43 PET tracer ACI-19626 demonstrated increased uptake in brain regions of patients with amyotrophic lateral sclerosis compared to healthy controls.

The data presented at the 2026 TDP43 Summit in Madison, Wisconsin, showed tracer uptake was higher in the brain stem and precentral gyrus, areas where TDP-43 pathology typically accumulates based on post-mortem studies. The company previously reported that ACI-19626 detected TDP-43 pathology in patients with genetic frontotemporal dementia.

The ongoing Phase 1 trial has two parts. Part 1, investigating ACI-19626 in healthy volunteers and patients with genetic FTD, has been

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Fri, 22 May 2026 07:00:00 -0400

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic lateral sclerosis (ALS)
Previously reported data also showed detection of TDP-43 in patients with genetically defined frontotemporal dementia (FTD)
Underlines potential for precision medicine enabling early diagnosis and intervention in multiple neurodegenerative diseases

Lausanne, Switzerland, May 22, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the presentation of new

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Fri, 22 May 2026 07:00:00 -0400

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic lateral sclerosis (ALS)
Previously reported data also showed detection of TDP-43 in patients with genetically defined frontotemporal dementia (FTD)
Underlines potential for precision medicine enabling early diagnosis and intervention in multiple neurodegenerative diseases

Form 4 AC Immune SA For: May 15 Filed by: Pfeifer Andrea

Mon, 18 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260518/26514235.html

Form 4 AC Immune SA For: May 15 Filed by: Pfeifer Andrea

Mon, 18 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260518/26514235.html

Form 144 AC Immune SA Filed by: Pfeifer Andrea

Fri, 15 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260515/26506321.html

Form 144 AC Immune SA Filed by: Pfeifer Andrea

Fri, 15 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260515/26506321.html

Form 6-K AC Immune SA For: May 15

Fri, 15 May 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260515/26500662.html